July 24, 2019 / 4:48 AM / 5 months ago

Lonza says on track to hit full-year 2019 targets

ZURICH, July 24 (Reuters) - Swiss drug ingredients maker Lonza Group said on Wednesday it is on pace to hit its 2019 goal of mid-to-high single-digit sales growth as double-digit gains in its drug and biotech unit in the first half offset weaker business elsewhere.

Sales in the first half rose 6.4% to 2.98 billion Swiss francs ($3.02 billion), while core earnings before interest, taxes, depreciation and amortisation rose 7% to 828 million francs, the Basel-based company said in a statement.

$1 = 0.9862 Swiss francs Reporting by John Miller Editing by Thomas Seythal

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below